225 related articles for article (PubMed ID: 27058414)
21. PP242 synergizes with suberoylanilide hydroxamic acid to inhibit growth of ovarian cancer cells.
Qin Y; Zhao X; Fang Y
Int J Gynecol Cancer; 2014 Oct; 24(8):1373-80. PubMed ID: 25188886
[TBL] [Abstract][Full Text] [Related]
22. Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model.
Chiu HW; Yeh YL; Wang YC; Huang WJ; Ho SY; Lin P; Wang YJ
Mol Cancer; 2016 Jun; 15(1):46. PubMed ID: 27286975
[TBL] [Abstract][Full Text] [Related]
23. Synergistically killing activity of aspirin and histone deacetylase inhibitor valproic acid (VPA) on hepatocellular cancer cells.
Li X; Zhu Y; He H; Lou L; Ye W; Chen Y; Wang J
Biochem Biophys Res Commun; 2013 Jun; 436(2):259-64. PubMed ID: 23726914
[TBL] [Abstract][Full Text] [Related]
24. Synergistic suppressive effect of PARP-1 inhibitor PJ34 and HDAC inhibitor SAHA on proliferation of liver cancer cells.
Liang BY; Xiong M; Ji GB; Zhang EL; Zhang ZY; Dong KS; Chen XP; Huang ZY
J Huazhong Univ Sci Technolog Med Sci; 2015 Aug; 35(4):535-540. PubMed ID: 26223923
[TBL] [Abstract][Full Text] [Related]
25. Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy.
Thomas S; Thurn KT; Biçaku E; Marchion DC; Münster PN
Breast Cancer Res Treat; 2011 Nov; 130(2):437-47. PubMed ID: 21298336
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.
Buurman R; Gürlevik E; Schäffer V; Eilers M; Sandbothe M; Kreipe H; Wilkens L; Schlegelberger B; Kühnel F; Skawran B
Gastroenterology; 2012 Sep; 143(3):811-820.e15. PubMed ID: 22641068
[TBL] [Abstract][Full Text] [Related]
27. Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-κB and autophagy on panobinostat cytotoxicity.
Mehrpouri M; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Momeny M; Bashash D
Eur J Pharmacol; 2020 May; 875():173050. PubMed ID: 32142770
[TBL] [Abstract][Full Text] [Related]
28. Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer.
Chan D; Zheng Y; Tyner JW; Chng WJ; Chien WW; Gery S; Leong G; Braunstein GD; Koeffler HP
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1507-14. PubMed ID: 23824064
[TBL] [Abstract][Full Text] [Related]
29. Panobinostat and Nelfinavir Inhibit Renal Cancer Growth by Inducing Endoplasmic Reticulum Stress.
Okubo K; Isono M; Asano T; Sato A
Anticancer Res; 2018 Oct; 38(10):5615-5626. PubMed ID: 30275179
[TBL] [Abstract][Full Text] [Related]
30. Regulation of apoptosis and autophagy by luteolin in human hepatocellular cancer Hep3B cells.
Lee Y; Kwon YH
Biochem Biophys Res Commun; 2019 Oct; 517(4):617-622. PubMed ID: 31383362
[TBL] [Abstract][Full Text] [Related]
31. HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2
Medon M; Vidacs E; Vervoort SJ; Li J; Jenkins MR; Ramsbottom KM; Trapani JA; Smyth MJ; Darcy PK; Atadja PW; Henderson MA; Johnstone RW; Haynes NM
Cancer Res; 2017 May; 77(10):2594-2606. PubMed ID: 28249907
[TBL] [Abstract][Full Text] [Related]
32. Morin Hydrate Sensitizes Hepatoma Cells and Xenograft Tumor towards Cisplatin by Downregulating PARP-1-HMGB1 Mediated Autophagy.
Pal Singh M; Pal Khaket T; Bajpai VK; Alfarraj S; Kim SG; Chen L; Huh YS; Han YK; Kang SC
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158052
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia.
Gopalakrishnapillai A; Kolb EA; McCahan SM; Barwe SP
Leuk Res; 2017 Jul; 58():91-97. PubMed ID: 28505595
[TBL] [Abstract][Full Text] [Related]
34. Beclin 1-mediated autophagy in hepatocellular carcinoma cells: implication in anticancer efficiency of oroxylin A via inhibition of mTOR signaling.
Zou M; Lu N; Hu C; Liu W; Sun Y; Wang X; You Q; Gu C; Xi T; Guo Q
Cell Signal; 2012 Aug; 24(8):1722-32. PubMed ID: 22560876
[TBL] [Abstract][Full Text] [Related]
35. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma.
Richardson PG; Laubach JP; Lonial S; Moreau P; Yoon SS; Hungria VT; Dimopoulos MA; Beksac M; Alsina M; San-Miguel JF
Expert Rev Anticancer Ther; 2015; 15(7):737-48. PubMed ID: 26051506
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells.
Catalano MG; Fortunati N; Pugliese M; Marano F; Ortoleva L; Poli R; Asioli S; Bandino A; Palestini N; Grange C; Bussolati B; Boccuzzi G
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1150-9. PubMed ID: 22563106
[TBL] [Abstract][Full Text] [Related]
37. Synergistic combination therapy with nanoliposomal C6-ceramide and vinblastine is associated with autophagy dysfunction in hepatocarcinoma and colorectal cancer models.
Adiseshaiah PP; Clogston JD; McLeland CB; Rodriguez J; Potter TM; Neun BW; Skoczen SL; Shanmugavelandy SS; Kester M; Stern ST; McNeil SE
Cancer Lett; 2013 Sep; 337(2):254-65. PubMed ID: 23664889
[TBL] [Abstract][Full Text] [Related]
38. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization.
Fischer C; Leithner K; Wohlkoenig C; Quehenberger F; Bertsch A; Olschewski A; Olschewski H; Hrzenjak A
Mol Cancer; 2015 Jan; 14():4. PubMed ID: 25608569
[TBL] [Abstract][Full Text] [Related]
39. Autophagy activation in hepatocellular carcinoma contributes to the tolerance of oxaliplatin via reactive oxygen species modulation.
Ding ZB; Hui B; Shi YH; Zhou J; Peng YF; Gu CY; Yang H; Shi GM; Ke AW; Wang XY; Song K; Dai Z; Shen YH; Fan J
Clin Cancer Res; 2011 Oct; 17(19):6229-38. PubMed ID: 21825039
[TBL] [Abstract][Full Text] [Related]
40. A novel mechanism of XIAP degradation induced by timosaponin AIII in hepatocellular carcinoma.
Wang N; Feng Y; Zhu M; Siu FM; Ng KM; Che CM
Biochim Biophys Acta; 2013 Dec; 1833(12):2890-2899. PubMed ID: 23906794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
